Compass Therapeutics: Potential Here, But Patience Required [Seeking Alpha]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Seeking Alpha
Tovecimig achieved a 17% ORR in 2L BTC, outperforming chemo alone and positioning CMPX for a potential $1B+ market opportunity if approved. Pipeline assets CTX-471 and CTX-8371 show early promise, with multiple Phase 2 basket trials and key readouts anticipated in 2026. Despite strong sell-side support and a cash runway into 2028, CMPX is not expected to be profitable until FY2029, warranting cautious position sizing for aggressive investors. An analysis around Compass Therapeutics follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » nopparit/iStock via Getty Images Shares of antibody-based oncology concern Compass Therapeutics, Inc. ( CMPX have rallied strongly since data from its lead asset, tovecimig, treating biliary tract cancer [BTC], received a cool reception. Even though it (in combination with chemo) only produced a 17% ORR in a second-line
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics (CMPX) had its "overweight" rating reaffirmed by Cantor Fitzgerald.MarketBeat
- Compass Therapeutics (CMPX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Compass Therapeutics (CMPX) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Compass Therapeutics (CMPX) had its "outperform" rating reaffirmed by Raymond James Financial, Inc..MarketBeat
- Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
CMPX
Earnings
- 3/5/26 - Beat
CMPX
Sec Filings
- 3/12/26 - Form S-8
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- CMPX's page on the SEC website